Health related quality of life and cardiac symptoms following admission for suspected MINOCA: A post-hoc analysis of the MINOCA-BAT randomized clinical trialKarolinska Inst, Danderyd Hosp, Dept Clin Sci, Div Cardiovasc Med, Stockholm, Sweden; Oslo Univ Hosp Ulleval, Dept Cardiol, Oslo, Norway; Univ Oslo, Inst Clin Med, Oslo, Norway.
Oslo Univ Hosp Ulleval, Dept Cardiol, Oslo, Norway; Univ Oslo, Inst Clin Med, Oslo, Norway.
Växjö Hosp, Dept Internal Med, Växjö, Sweden.
Lund Univ, Skane Univ Hosp, Dept Cardiol, Clin Sci, Lund, Sweden.
Univ Leeds, Leeds Inst Cardiovasc & Metab Med, Leeds, England; Leeds Teaching Hosp NHS Trust, Dept Cardiol, Leeds, England.
Karolinska Inst, Danderyd Hosp, Dept Clin Sci, Div Cardiovasc Med, Stockholm, Sweden;;Karolinska Inst, Dept Clin Sci & Educ, Sodersjukhuset, Stockholm, Sweden.
Swedish Heart & Lung Assoc, Stockholm, Sweden.
Univ Gothenburg, Inst Med, Sahlgrenska Acad, Dept Mol & Clin Med, Gothenburg, Sweden; Sahlgrens Univ Hosp, Dept Cardiol, Gothenburg, Sweden.
NYU, Ctr Womens Cardiovasc Hlth, Leon H Charney Div Cardiol, Cardiovasc Clin Res Ctr,Dept Med,Grossman Sch Med, New York, NY USA.
Auckland City Hosp, Green Lane Cardiovasc Serv, Auckland, New Zealand.
Adelaide Univ, Coll Hlth, Sch Med, Adelaide, Australia; SA Hlth, Cent Adelaide Local Hlth Network, Dept Cardiol, Adelaide, Australia.
Show others and affiliations
2026 (English)In: American Heart Journal Plus: Cardiology Research and Practice, E-ISSN 2666-6022, Vol. 70, article id 100856Article in journal (Refereed) Published
Abstract [en]
Background
Myocardial infarction (MI) with non-obstructive coronary arteries (MINOCA) accounts for 6–8% of all MIs and is more common in women than men. After an episode of MINOCA, patients may experience a substantial symptom burden and reduced health-related quality of life (HRQoL). The aim of this post-hoc analysis was to describe clinical characteristics, residual symptoms and HRQoL, including sex differences in patients with a working diagnosis of MINOCA and preserved left ventricular ejection fraction (LV-EF).
Methods
Randomized Evaluation of Beta Blocker and ACE-Inhibitor/Angiotensin Receptor Blocker Treatment in MINOCA patients (MINOCA-BAT) was an international clinical trial. Patients with a working diagnosis of MINOCA and LV-EF ≥ 40% were randomized to beta-blocker versus no beta-blocker and ACEI/ARB versus no ACEI/ARB. The trial was prematurely terminated after 192 enrolled participants (median age 59; 63% women). Clinical events, symptoms and HRQoL (EQ-5D-3L) were assessed at 7 weeks and 12 months after the index event.
Results
The cohort represented a low-risk population. At one year, one patient had died, one had a re-infarction, 14% reported chest pain and 9% dyspnea. Median EQ-5D index scores did not change significantly between 7 weeks and 12 months (0.86 vs. 0.78) and were comparable to age-matched general population norms. Women reported slightly lower HRQoL than men.
Conclusions
Patients with a working diagnosis of MINOCA and preserved LV-EF constitute a low-risk population and demonstrate a favorable prognosis with symptom resolution within one year. Their HRQoL appears broadly similar to that observed in the general population, with only modest differences between the sexes.
Place, publisher, year, edition, pages
Elsevier, 2026. Vol. 70, article id 100856
Keywords [en]
Myocardial infarction (MI) with non, obstructive coronary arteries (MINOCA), Health related quality of life, Cardiac symptoms, Sex
National Category
Cardiology and Cardiovascular Disease
Identifiers
URN: urn:nbn:se:uu:diva-596324DOI: 10.1016/j.ahjo.2026.100856ISI: 001845241400001PubMedID: 42602980Scopus ID: 2-s2.0-105046538804OAI: oai:DiVA.org:uu-596324DiVA, id: diva2:2094895
Part of project
Randomized Evaluation of Beta-blocker and ACEI/ARB Treatment in MINOCA patients (MINOCA-BAT)., Swedish Research Council
Funder
Swedish Research Council, 2017-004782026-08-242026-08-242026-08-24Bibliographically approved